The role of tissue factor pathway inhibitor in atherosclerosis and arterial thrombosis [0.03%]
组织因子途径抑制物在动脉粥样硬化和动脉血栓形成中的作用
Kristien Winckers,Hugo ten Cate,Tilman M Hackeng
Kristien Winckers
Tissue factor pathway inhibitor (TFPI) is the main inhibitor of tissue factor (TF)-mediated coagulation. In atherosclerotic plaques TFPI co-localizes with TF, where it is believed to play an important role in attenuating TF activity. Findin...
Charles H Lawrie
Charles H Lawrie
MicroRNAs (miRNAs) have become one of the hottest topics in biology over recent years, but remarkably have only been formally recognized for just over 10 years. These endogenously produced short (19-24 nt) non-coding RNAs have introduced an...
Antonio Palumbo,Roberto Mina
Antonio Palumbo
Two-thirds of patients with multiple myeloma are aged 65 years or more and the prevalence of multiple myeloma in elderly patients is expected to rise in the next future. Patients older than 65 years are usually considered ineligible for tra...
Regulating the regulators in cancer-immunosuppression in multiple myeloma (MM) [0.03%]
肿瘤免疫抑制在多发性骨髓瘤中的调控研究
Sylvia Feyler,Peter J Selby,Gordon Cook
Sylvia Feyler
An effective immune response requires a prompt but measured action against the pathological insult, to prevent over-zealous inflammatory-mediated tissue destruction. In cancer, defective or incompetent immune responses may paradoxically res...
Lori-Ann Linkins
Lori-Ann Linkins
Vitamin K antagonists are widely used for the prevention of stroke due to atrial fibrillation, treatment and secondary prevention of venous thromboembolism, prevention of valvular thromboembolism in patients with prosthetic heart valves, an...
Current status and future prospects for the prophylactic management of hemophilia patients with inhibitor antibodies [0.03%]
我国血友病患者抑制物预防治疗的现状与展望
Jerome M Teitel,Michelle Sholzberg
Jerome M Teitel
Inhibitor antibodies to factor VIII arise in a substantial minority of patients with hemophilia A treated with replacement therapy; factor IX inhibitors in treated hemophilia B patients are considerably less common. As replacement therapy i...
Blood-derived biomaterials and platelet growth factors in regenerative medicine [0.03%]
血液衍生生物材料和血小板生长因子在再生医学中的应用
Thierry Burnouf,Hadi Alphonse Goubran,Tim-Mo Chen et al.
Thierry Burnouf et al.
Several biomaterials can be obtained from human blood. Some are used for clinical indications requiring a high content in fibrinogen, while others are used because they contain multiple platelet growth factors. Mimicking thrombin-induced ph...
Giampaolo Minetti,Stephane Egée,Daniel Mörsdorf et al.
Giampaolo Minetti et al.
Red blood cell research is important for both, the clinical haematology, such as transfusion medicine or anaemia investigations, and the basic research fields like exploring general membrane physiology or rheology. Investigations of red blo...
The emerging concept of residual ADAMTS13 activity in ADAMTS13-deficient thrombotic thrombocytopenic purpura [0.03%]
ADAMTS13活性残留的新兴概念在ADAMTS13缺陷性血栓性血小板减少性紫癜中的作用
Luca A Lotta,Haifeng M Wu,Khaled M Musallam et al.
Luca A Lotta et al.
Thrombotic thrombocytopenic purpura (TTP) is a rare, life-threatening disease characterized by acute episodes of widespread microvascular thrombosis. The discovery that the plasmatic activity of the von Willebrand factor cleaving protease, ...
Linda M Scott
Linda M Scott
Considerable attention has focused on the gain-of-function mutations in the Janus kinase-2 (JAK2) tyrosine kinase that are detectable in most patients with a myeloproliferative neoplasm. Activating mutations that target JAK2, as well as JAK...